SEC Tracker
Get the app

Allarity Therapeutics ALLR

Allarity Therapeutics terminated a stock purchase agreement

Item 1.02 Ends material agreement

Form
8-K
Filed
Importance
Notable
  1. Terminated on October 28, 2026
  2. Agreement allowed up to $6.0 million in stock sales
  3. No early termination penalty
  4. Company plans to seek alternative financing

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Allarity Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old